Relevant bibliographies by topics / Anticoagulant effects

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Anticoagulant effects'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anticoagulant effects.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anticoagulant effects"

1

Kreuter, Michael, Marlies S. Wijsenbeek, Martina Vasakova, et al. "Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis." European Respiratory Journal 47, no. 6 (2016): 1776–84. http://dx.doi.org/10.1183/13993003.02087-2015.

Full text
Abstract:
Procoagulant and antifibrinolytic activity has been associated with idiopathic pulmonary fibrosis (IPF); however, investigation of anticoagulant therapy in IPF has suggested deleterious effects. This post hoc analysis evaluated the effect of medically indicated anticoagulation on mortality and other clinical outcomes in IPF.Patients randomised to placebo (n=624) from three controlled trials in IPF were analysed by oral anticoagulant use. End-points included all-cause and IPF-related mortality, disease progression, hospitalisation, and adverse events, over 1 year.At baseline, 32 (5.1%) patients
APA, Harvard, Vancouver, ISO, and other styles
2

Moore, Gary W., Savita Rangarajan, and Geoffrey F. Savidge. "The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies." Clinical and Applied Thrombosis/Hemostasis 14, no. 3 (2008): 332–37. http://dx.doi.org/10.1177/1076029607305099.

Full text
Abstract:
Lupus anticoagulants are a heterogeneous group of autoantibodies detected by their effects on phospholipid-dependent coagulation assays. Persistent lupus anticoagulants are associated with thrombotic disease, but not all are clinically significant. Antibody heterogeneity and reagent and test variability dictate that at least 2 tests, of different types, should be used to screen lupus anticoagulants. The objective of this study was to investigate whether the activated seven lupus anticoagulant assay detects clinically significant antibodies. Eighty-two patients with antiphospholipid syndrome (A
APA, Harvard, Vancouver, ISO, and other styles
3

Fareed, Jawed, Michael J. Moorman, Walter Jeske, and Debra Hoppensteadt. "Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs." Blood 122, no. 21 (2013): 4804. http://dx.doi.org/10.1182/blood.v122.21.4804.4804.

Full text
Abstract:
Introduction Defibrotide represents a single stranded mammalian DNA derived agent originally developed for anti-thrombotic and anti-ischemic indications. Defibrotide is currently used to treat or prevent failure of normal blood flow (Veno-occlusive disease, VOD) in the liver of patients who had bone marrow transplants or received drugs such as oral estrogens and mercatopurine. Defibrotide is a polypharmocologic agent with multiple sites of actions, which include anti-inflammatory and vaso-facilitatory effects. The purpose of this investigation is to determine potential interactions of defibrot
APA, Harvard, Vancouver, ISO, and other styles
4

Antovic, J., A. Antovic, E. M. Norberg, M. Berndtsson, and M. Skeppholm. "FRI0593 Effects of New (Direct) Oral Anticoagulants on Lupus Anticoagulant Assays." Annals of the Rheumatic Diseases 74, Suppl 2 (2015): 642.3–643. http://dx.doi.org/10.1136/annrheumdis-2015-eular.5847.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Young, Guy, Karyn E. Yonekawa, Peggy Nakagawa, Rachelle Blain, Amy E. Lovejoy, and Diane J. Nugent. "Recombinant Factor VIIa Reverses the Anticoagulant Effects of Argatroban, Bivalirudin, Fondaparinux, Enoxaparin, and Heparin as Assessed Ex Vivo by Thromboelastography." Blood 104, no. 11 (2004): 1867. http://dx.doi.org/10.1182/blood.v104.11.1867.1867.

Full text
Abstract:
Abstract BACKGROUND: The novel anticoagulants fondaparinux (Fond), argatroban (Arg), and bivalirudin (Biv) are being used increasingly for a variety of indications, even replacing heparin and warfarin in certain settings. While heparin and warfarin have antidotes (protamine and vitamin K, respectively), the newer agents lack known antidotes. Recombinant factor VIIa (rFVIIa) has reversed the effects of some novel anticoagulants in in vitro and animal studies. We evaluated the ability of rFVIIa to reverse the anticoagulant effects of Fond, Arg, Biv, unfractionated heparin (Hep), and enoxaparin (
APA, Harvard, Vancouver, ISO, and other styles
6

Kalinin, E. P., N. N. Buslaeva, and D. I. Boyarintsev. "Biological effects and assessment of acute toxicity of anticoagulants extracted from plants." Medical Science And Education Of Ural 21, no. 4 (2020): 27–29. http://dx.doi.org/10.36361/1814-8999-2020-21-4-27-29.

Full text
Abstract:
The aim of the study – was to study the biological effects and assess acute toxicity in an in vivo experimental study when injecting plant-derived effectors with an anticoagulant effect to laboratory animals. Materials and methods. As the studied effectors, plant anticoagulants obtained from the leaves of blueberry (Vaccinium myrtillus) and peloid, which were obtained in the previous studies, were used. The biological effect of effectors was evaluated by indicators characterizing coagulation and platelet hemostasis when administered to laboratory animals. Acute toxicity was assessed by the sur
APA, Harvard, Vancouver, ISO, and other styles
7

Blennerhassett, Richard, Emmanuel Favaloro, and Leonardo Pasalic. "Novel (Oral) Anticoagulant Challenges in Surgery." Seminars in Thrombosis and Hemostasis 43, no. 07 (2017): 706–15. http://dx.doi.org/10.1055/s-0037-1602667.

Full text
Abstract:
SummaryNon-vitamin K oral anticoagulants (NOACs) are a relatively recent therapeutic modality for the prevention of systemic thromboembolic complications of atrial fibrillation and the prevention and management of venous thromboembolic disease. Approved indications for this class of anticoagulants are likely to further expand as the results of ongoing and new clinical trials are published and clinical experience grows. Despite their convenience compared with traditional methods of anticoagulation, there remain a few potential pitfalls associated with their use in the perioperative setting. In
APA, Harvard, Vancouver, ISO, and other styles
8

Masood, Soofia, Debra Hoppensteadt, Josephine Cunanan, et al. "Population Based Differences in the Anticoagulant and Antiprotease Responses of Newer and Oral Anticoagulant Drugs." Blood 120, no. 21 (2012): 3421. http://dx.doi.org/10.1182/blood.v120.21.3421.3421.

Full text
Abstract:
Abstract Abstract 3421 Introduction: Most of the screening of the newer anticoagulant drugs is usually carried out in normal human blood derived plasma and its products. Therefore endogenous compositional factors in different patient groups which may result in altering the anticoagulant and antiprotease effects of these drugs are not taken into account. Recently an oral anti-IIa agent Dabigatran and an anti-Xa agent namely Rivaroxaban are approved for clinical usage in the US. An additional anti-Xa drug namely Apixaban is approved in Europe and is under review by the US FDA. The pharmacologic
APA, Harvard, Vancouver, ISO, and other styles
9

DIACONU, Camelia, Giorgiana DEDIU, Mădălina ILIE, and Mihaela Adela IANCU. "Treatment with new oral anticoagulants in the family medicine practice." Romanian Journal of Medical Practice 10, no. 4 (2015): 329–32. http://dx.doi.org/10.37897/rjmp.2015.4.4.

Full text
Abstract:
Vitamin K antagonists represented for more than 50 years the only oral anticoagulant treatment option, though encumbered by numerous food and drug interactions, with direct impact on the safety and efficacy of this treatment. The frequent complications of anticoagulant treatment with vitamin K antagonists led to the need for the emergence of new oral anticoagulants (NOAC). The main NOACs used today are dabigatran, rivaroxaban and apixaban. NOAC have a number of advantages over antivitamin K anticoagulants: fewer drug interactions, no food interactions, rapid onset of the anticoagulant action,
APA, Harvard, Vancouver, ISO, and other styles
10

Koyama, Takatoshi, and Misako Shibakura. "Anticoagulant Effects of Synthetic Retinoids." Leukemia & Lymphoma 31, no. 1-2 (1998): 71–80. http://dx.doi.org/10.3109/10428199809057586.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anticoagulant effects"

1

Daniells, Laura J. "The non-target effects of anticoagulant rodenticides." Thesis, University of Reading, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.559253.

Full text
Abstract:
The exposure of primary and secondary non-target species to Second Generation Anticoagulant Rodenticides (SGARs) is widespread and is a cause for concern amongst conservationists. Levels found in wild non-target species range from trace amounts to lethal levels and occur in up to 81% of barn owl carcasses surveyed. The harm caused by low level AR residues carried by many animals in the wild is not well understood, as is the relative toxicity of the different AR compounds to bird species. My experimental work investigated both sub-lethal residues carried by laboratory mice, Mus musculus, and th
APA, Harvard, Vancouver, ISO, and other styles
2

Pratt, Sarah Kathryn. "A study of the disposition of vitamin K←1 and the enantiomers of warfarin in relation to pharmacodynamic response." Thesis, University of Liverpool, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.291736.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Butler, Sarah Elizabeth. "The sub-lethal effects of second generation anticoagulant rodenticides on birds." Thesis, University of Leicester, 2014. http://hdl.handle.net/2381/29133.

Full text
Abstract:
There are high economic, human health and environmental reasons for using Second Generation Anticoagulant Rodenticides (SGARs) but there is also widespread non-target exposure to a large number of bird of prey species, such as red kites and barn owls. My overall aim was to assess the potential biochemical and physiological impacts of sub-lethal exposure on birds. I determined environmentally realistic doses of two SGARs, brodifacoum (high acute toxicity) and difenacoum (most widely used and detected in wildlife), in a model species, Japanese quail (Coturnix coturnix japonica), and used these d
APA, Harvard, Vancouver, ISO, and other styles
4

Fergusson, D. "The effects of 4-hydroxycoumarin anticoagulant rodenticides on birds and the development of techniques for non-destructively monitoring their ecotoxicological effect." Thesis, University of Reading, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.239503.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fisher, P. M. "Residual concentrations and persistence of the anticoagulant rodenticides brodifacoum and diphacinone in fauna." Lincoln University, 2009. http://hdl.handle.net/10182/930.

Full text
Abstract:
Brodifacoum is a highly effective anticoagulant rodenticide that presents a secondary hazard to some non-target wildlife. The high acute toxicity of brodifacoum to mammals and birds, and its prolonged persistence in liver predicates secondary risk to predators and scavengers of poisoned rodents. Hence there is a need to improve ability to monitor and predict hazards of brodifacoum to non-targets, and optimise use patterns accordingly. Use of a less persistent anticoagulant rodenticide, diphacinone, is an alternative approach currently under investigation in New Zealand. This thesis describes a
APA, Harvard, Vancouver, ISO, and other styles
6

Itonaga, Tatsuya. "The N-terminal lectin-like domain of thrombomodulin reduces acute lung injury without anticoagulant effects in a rat cardiopulmonary bypass model." Doctoral thesis, Kyoto University, 2021. http://hdl.handle.net/2433/263532.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pham, Thuy-Hang. "Thérapeutique anticoagulante dans un service de cardiologie : prescription et suivi thérapeutique." Paris 5, 1991. http://www.theses.fr/1991PA05P050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pitt, Tracy Shawn. "Effects of temperature and anticoagulant on the in vitro quantitation of Leukocyre Expressed Mac-1 and Post-traumatic assay to predict the development of ARDS." Youngstown State University / OhioLINK, 2001. http://rave.ohiolink.edu/etdc/view?acc_num=ysu996864777.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Paoli, Michèle. "Les hématomes du muscle psoas iliaque apparus au cours d'un traitement anticoagulant : à propos de sept observations." Bordeaux 2, 1990. http://www.theses.fr/1990BOR25024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bissolokele, Matoundou Pascal. "Leucémie à tricholeucocytes anticoagulant circulant antithrombinase et interféron alpha recombinant : à propos d'un cas." Bordeaux 2, 1995. http://www.theses.fr/1995BOR2M097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Anticoagulant effects"

1

Warkentin, Theodore E., and Andreas Greinacher. Heparin-induced thrombocytopenia. 4th ed. Informa Healthcare, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Scott, Deborah. Determination of the effect of activated protein C (APC) upon the anticoagulant activity of various forms of heparin as determined in-vitro in normal human plasma. The Author], 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Thrombosis, embolism and bleeding. ICR Publ., 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Handbook of compounds with anti-inflammatory and anti-platelet aggregation activities isolated from plants. Nova Science Publishers, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

National Toxicology Program (U.S.). NTP technical report on the toxicology and carcinogenesis studies of triamterene (CAS no. 396-01-0) in F344/N rats and B6C3F mice (feed studies). U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Assessing Anticoagulant Resistance in Rats and Coagulation Effects in Birds Using Small-Volume Blood Samples. Not Avail, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dwyer, Scott Douglas. Effects of anesthetics, anticoagulants, and rat strain on rat platelet aggregation. 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Heparin-Induced Thrombocytopenia, Fourth Edition (Fundamental and Clinical Cardiology). 4th ed. Informa Healthcare, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1960-, Warkentin Theodore E., and Greinacher Andreas, eds. Heparin-induced thrombocytopenia. 4th ed. Informa Healthcare USA, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

El Kenz, Hanane, and Philippe Van der Linden. The physiology of blood in anaesthetic practice. Edited by Jonathan G. Hardman. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199642045.003.0011.

Full text
Abstract:
Following the discovery of the ABO blood groups by Landsteiner in 1901, Albert Hustin described the first transfusion of a whole blood unit in 1914. The modern transfusion era really begins in 1916 with the discovery of sodium citrate as an anticoagulant by the same physician, allowing blood conservation in dedicated packs. Since that time, many advances have been made especially over the past two decades in the storage, the conservation, and the laboratory testing of blood components and in transfusion medicine practice. Transfusion of whole blood has been replaced by blood component therapy,
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Anticoagulant effects"

1

Lever, Rebecca, and Clive P. Page. "Non-anticoagulant Effects of Heparin: An Overview." In Heparin - A Century of Progress. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-23056-1_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Stuart, J., and I. Juhan-Vague. "Anticoagulant effects on the measurement of erythrocyte filterability." In Blood Filtration and Blood Cell Deformability. Springer Netherlands, 1985. http://dx.doi.org/10.1007/978-94-009-5008-5_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ofosu, F. A. "Mechanisms for the Anticoagulant Effects of Synthetic Antithrombins." In Advances in Experimental Medicine and Biology. Springer US, 1993. http://dx.doi.org/10.1007/978-1-4899-2418-6_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Barrowcliffe, T. W. "LMW Heparin: Relationship Between Antithrombotic and Anticoagulant Effects." In Advances in Experimental Medicine and Biology. Springer US, 1992. http://dx.doi.org/10.1007/978-1-4899-2444-5_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

López-Perea, Jhon J., and Rafael Mateo. "Secondary Exposure to Anticoagulant Rodenticides and Effects on Predators." In Emerging Topics in Ecotoxicology. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-64377-9_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Amirkhosravi, Ali, Shaker A. Mousa, Mildred Amaya, et al. "Assessment of Anti-Metastatic Effects of Anticoagulant and Antiplatelet Agents Using Animal Models of Experimental Lung Metastasis." In Anticoagulants, Antiplatelets, and Thrombolytics. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-803-4_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mousa, Shaker A. "Antithrombotic Effects of Naturally Derived Products on Coagulation and Platelet Function." In Anticoagulants, Antiplatelets, and Thrombolytics. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-803-4_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pineo, Graham F., and Russell D. Hull. "Effects of Anticoagulants on Cancer: Heparins." In Cancer Treatment and Research. Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-79962-9_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Witiw, Christopher D., Laureen D. Hachem, and Michael G. Fehlings. "Classes of Drugs and Blood Products for Acute Reversal of Anticoagulant Effect." In Anticoagulation and Hemostasis in Neurosurgery. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-27327-3_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Brogi, E., F. Coccolini, and F. Forfori. "Reversing the Effect of Anticoagulants Safety in Patients Undergoing Emergency Surgery." In Emergency General Surgery in Geriatrics. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-62215-2_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anticoagulant effects"

1

Taha, Ali, Caroline McCloskey, Theresa Craigen, and Wilson Angerson. "PTU-069 Antiplatelet versus anticoagulant effects in non-variceal upper gastrointestinal bleeding." In British Society of Gastroenterology Annual Meeting, 17–20 June 2019, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-bsgabstracts.285.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Corte-lazzo, D., M. Galli, P. Viero, and T. Barbui. "INTERACTION BETWEEN LUPUS ANTICOAGULANT AND PLATELETS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644230.

Full text
Abstract:
Lupus Anticoagulants (LAC) are IgG or IgM immunoglobulins which interfere with phospholipid-dependent coagulation tests and actively react also with platelet wall phospholipids. This interaction may result in platelet quantitative and qualitative defects. We have examined 10 patients with LAC diagnosed on the basis of the commonly accepted criteria (Working Party reccomandations, 1983). Four had concomitant Systemis Lupus Erythematosus, one Waldenstrom's disease (W. D.) and five no apparently underlying disease. Only the case with W. D. presented bleeding tendency, whereas the others had a his
APA, Harvard, Vancouver, ISO, and other styles
3

Pangrazzl, J., P. Oreste, G. Torri, A. Maggi, M. B. Donati, and B. Casu. "BLEEDING EFFECTS ASSOCIATED WITH HEPARIN contaminants." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644177.

Full text
Abstract:
Clinical use of heparin as an antithrombotic drug Is limited by the risk of excessive bleeding, generally ascribed to the anticoagulant activity of this mucopolysaccharide.Unexpectedly, some low molecular weight heparins with reduced anticoagulant activity are reported to cause bleeding in clinical and experimental studies. To approach this problem, a number of heparin preparations with various molecular weights were characterized by analysis of their 13C-NMR spectra. The bleeding potential of the same heparins was tested by measuring the "template" bleeding time (BT, a method exploring the me
APA, Harvard, Vancouver, ISO, and other styles
4

Schorer, Anna E., and Kathleen V. Watson. "THE "LUPUS ANTICOAGULANT" INDUCES FUNCTIONAL CHANGES IN ENDOTHELIAL CELLS AND PLATELETS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643656.

Full text
Abstract:
The presence of the "lupus anticoagulant" (LA) predicts a clinical syndrome of excessive arterial, venous and microvascu-lar thrombosis. LA is an antibody which reacts with negatively charged phospholipid (PL) species in vitro. Since PL is involved in many aspects of the regulation of thrombosis, we postulated that LA might modify one or more of the membrane-(PL-dependent reactions of platelets and endothelial cells (EC). Blood samples from 20 patients with a history of thrombosis were tested for the presence of LA (kaolin PTT) and titres determined. LA-positive (LA+) sera and plasma were comp
APA, Harvard, Vancouver, ISO, and other styles
5

Hoppensteadt, D., A. Kumar, J. Fareed, and J. Mardigian. "STUDIES ON THE ANTICOAGULANT AND ANTITHROMBOTIC ACTIONS OF DERMATANS AND THEIR SULFATED DERIVATIVES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643241.

Full text
Abstract:
Non-antithrombin III mediated effects such as interaction with heparin cofactor II, modulation of endothelium and polymorphonuclear leukocytes contribute to the overall antithrombotic effects of glycosaminoglycans. In order to study the role of these dermatans, we investigated their in vitro anticoagulant effects using the clot based (PT, APTT, TT, and Heptest), antiprotease (anti IIa and anti Xa) and Thromboplastin C activated fibrinopeptide A generation test. The in vivo antithrombotic actions were investigated, against activated and non activated prothrombin complex concentrates, and in com
APA, Harvard, Vancouver, ISO, and other styles
6

Wehmeier, A., and W. Schneider. "FACTORS AFFECTING PLATELET VOLUME ANALYSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643538.

Full text
Abstract:
Parameters of platelet volume have become widely available with the introduction of automated platelet counters. However, variant sample processing and in vitro platelet activation have prevented standardization of platelet volume analysis. We investigated the influence of anticoagulation, storage, temperature, and the presence or absence of RBC on platelet volume. Mean platelet volume (MPV) and the mode of the distribution were calculated from the platelet volume distribution curve recorded with the impedance method and plotted in 27 classes between 1.2 and 22 fl. The effects of EDTA (.335%),
APA, Harvard, Vancouver, ISO, and other styles
7

Dharavath, B., O. Iqbal, D. Hoppensteadt, E. Bontekoe, and J. Fareed. "Whole blood anticoagulant effects of Sulodexide as measured by activated clotting time and their neutralization by Protamine sulfate." In 65th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1728154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ehrlich, H. J., N. U. Bang, N. L. Esmon, and C. T. Esmon. "IN VIVO BEHAVIOR OF DETERGENT SOLUBILIZED PURIFIED RABBIT THROMBOMODULIN INJECTED INTO RABBITS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643966.

Full text
Abstract:
Thrombomodulin (TM) is a thrombin (T) endothelial cell membrane receptor; the TM-T complex readily activates protein C resulting in anticoagulant activity. We investigated the biological effects of detergent solubilized purified rabbit TM upon i.v. injection into rabbits. 125I-labelled TM (lactoperoxidase method) disappeared from the circulation to a t 1/2 of 2.5 h.The administration to rabbits of 2 doses of 50 μg/kg endotoxin 24 h apart did not accelerate the turnover rate of TM. In vitro tests demonstrated that .27 nM TM was required to significantly prolong the activated partial thromboplas
APA, Harvard, Vancouver, ISO, and other styles
9

Roncaglioni, M. C., I. Reyers, A. P. Bolognese Dolessandro, C. Cerletti, M. B. Donati, and G. de Gaetano. "SALICYLATE-WARFARIN INTERACTION: EFFECTS ON SYSTEMIC ANTICOAGULATION, BLEEDING TIME, AND EXPERIMENTAL VENOUS THROMBOSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643270.

Full text
Abstract:
The potential benefit of the aspirin/warfarin association as an antithrombotic treatment has been matter of debate in view of the major haemorrhagic effect reported with this drug combination. We have tested the effect of such association in a model of venous thrombosis already shown to be prevented by a fully anticoagulant schedule of warfarin. CD-COBS male rats were treated for three days with either warfarin (0.1 mg/kg i.v. once a day) or salicylate (175 mg/kg i.p. twice a day) or their combination (W+S). Systemic anticoagulation (thrombotest), template bleeaing time and occurrence of exper
APA, Harvard, Vancouver, ISO, and other styles
10

Takamatsu, J., H. Saito, T. Kamiya, Y. Muranaka, Y. F. Minami, and H. T. Fan. "A NEW MUCOPOLYSACCHARIDE FROM STICHPUS JAPONICUS(SEA CUCUMBER) AND ITS ANTICOAGULANT PRORETIES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644185.

Full text
Abstract:
A new mucopolysaccharide(FGAG) has been isolated from the cell wall of Stichopus japonicua. The molecular weight of FGAG is about 50,000. The component sugar of the FGAG are identified as galactosamine, glucuronic acid, fucose and sulfate with the molar ratioof 1:0.94:0.84:3.60,respectively. The anticoagulant effects of FGAG were studied. At low concentration(lμg/ml), FGAG completely inhibited the rabbit plateletaggregation induced by thrombin and prolonged thrombin time of not only human plasma but purified fibrinogen solution to a similar extent, suggesting that action of FGAG is not depend
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anticoagulant effects' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography